Hal Hirte

Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.

Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.

Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.

Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.

Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.